Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: Effects on intragastric pH and comparison with esomeprazole in healthy volunteers

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 6, 2004, Pages 655-662

  Galmiche, J P ^a   Bruley Des Varannes, S ^a   Ducrotte P ^b   Sacher Huvelin, S ^a   Vavasseur, F ^a   Taccoen, A ^c   Fiorentini, P ^c   Homerin, M ^c  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c Negma GILD ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENATOPRAZOLE; BENZIMIDAZOLE; ESOMEPRAZOLE; GASTRIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR;

ABDOMINAL PAIN; ADULT; ARTICLE; BRONCHITIS; BRONCHOSPASM; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG TOLERABILITY; GASTRIN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPERBILIRUBINEMIA; MALE; NIGHT; NORMAL HUMAN; OPEN STUDY; OUTCOMES RESEARCH; PH MEASUREMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; STOMACH ACID SECRETION; STOMACH PH; TENDON DISEASE; VOMITING;

ADOLESCENT; ADULT; ANTI-ULCER AGENTS; CROSS-OVER STUDIES; GASTRIC ACID; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; IMIDAZOLES; MALE; OMEPRAZOLE; PROTON PUMPS; PYRIDINES;

EID: 1842429772     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01893.x     Document Type: Article

References (27)

1. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastrooesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 59-67.
2. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99: 345-51.
3. Chiba N, De Gara CJ, Wilkinson JM. Speed of healing and symptom relief in grade II to IV gastro-oesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
4. Spencer CM, Faulds D. Esomeprazole. Drugs 2000; 60: 321-9.
5. Andersson T, Röhss K, Bredberg E, Hassan-Alin M. Pharmacokinettcs and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001; 15: 1563-9.
6. Hatlebakk JG. Review article: gastric acidity - comparison of esomeprazole with other proton pump inhibitors. Aliment Pharmacol Ther 2003; 17: 10-5.
7. Dent J. Review article: initial therapy of reflux disease with esomeprazole. Aliment Pharmacol Ther 2003; 17(Suppl. 1): 18-20.
8. Holloway RH, Dent J, Narielvala F, Mackinnon AM. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 1996; 38: 649-54.
9. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115: 1335-9.
10. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93: 763-7.
11. Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12: 1231-4.
12. Katsube T, Adachi K, Kawamura A, et al. Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther 2000; 14: 1049-56.
13. 2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122: 625-32.
14. Tytgat GNJ. Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatol 2001; 13(Suppl. 1): S29-33.
15. +-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats. Meth Find Exp Clin Pharmacol 1999; 24: 114-22.
16. +-ATPase inhibitor, in gastric acid secretion in dogs. J Pharm Pharmacol 1999; 51: 457-64.
17. Ficheux H, Domagala F. Pharmacokinetics of tenatoprazole, a novel proton pump inhibitor, in healthy male Caucasian volunteers. Gastroenterology 2003; 124: S1608.
18. Bruley des Varannes S, Levy P, Lartigue S, Dellatolas F, Lemaire M, Galmiche JP. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994; 8: 309-14.
19. Galmiche JP, Bruley des Varannes S. Gastric pH-metry: clinical relevance. In: Scarpignato C, Bianchi Porro G, eds. Clinical Investigation of Gastric Function. Frontiers in Gastrointestinal Research, Vol. 17. Basel: Karger, 1990: 32-54.
20. Ohning GV, Barbuti RC, Kovacs TOG, Sytnik B, Humphries TJ, Walsh JH. Rabeprazole produces rapid, potent and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 701-8.
21. Armstrong D, Bair D, James C, Tanser L, Escobedo S, Nevin K. Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. Aliment Pharmacol Ther 2003; 18: 705-11.
22. Cheer SM, Prakash A, Faulds D, Lamb HM. Pantoprazole. An update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003; 63: 101-32.
23. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: 1079-89.
24. Tolman KG, Sanders SW, Buchi KN, Karol MD, Jennings DE, Ringham GL. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997; 24: 65-70.
25. Scott LE, Dunn CJ, Mallarkey G, Sharpe M. Esomeprazole. A review of its use in the management of acid-related disorders. Drugs 2002; 62: 1503-38.
26. Stedman CAM, Barclay M. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000: 14: 963-78.
27. Preston JW. Clinical significance of hypergastrinaemla: relevance to gastrin monitoring during omeprazole therapy. Digestion 1992; 51(Suppl. 1): 102-14.